News-Medical.Net July 29, 2024
In a recent study published in The Journal of the American Medical Association, a team of researchers in Sweden examined whether the ratio of phosphorylated tau 217 protein to non-phosphorylated tau 217 protein in plasma, determined through a blood test could be combined with the amyloid probability score 2 (APS2) and be used in primary and secondary care facilities to accurately diagnose Alzheimer’s disease and lower the misdiagnosis rates for the disease.
Background
Research indicates that 20% of women and 10% of men develop Alzheimer’s disease-related dementia. Individuals exhibiting the early symptoms of cognitive deficits visit primary care facilities, but a very small portion of those patients are referred further to secondary care centers. The rate of misdiagnoses of symptomatic...
Today's Sponsors
Today's Sponsor